Cathy Tangen

3.2k total citations · 1 hit paper
36 papers, 2.3k citations indexed

About

Cathy Tangen is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Cathy Tangen has authored 36 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 15 papers in Surgery and 9 papers in Oncology. Recurrent topics in Cathy Tangen's work include Bladder and Urothelial Cancer Treatments (13 papers), Prostate Cancer Treatment and Research (13 papers) and Urinary and Genital Oncology Studies (11 papers). Cathy Tangen is often cited by papers focused on Bladder and Urothelial Cancer Treatments (13 papers), Prostate Cancer Treatment and Research (13 papers) and Urinary and Genital Oncology Studies (11 papers). Cathy Tangen collaborates with scholars based in United States, Canada and Türkiye. Cathy Tangen's co-authors include E. David Crawford, Richard Sylvester, Hendrik Van Poppel, Robert C. Flanigan, G. Mickisch, Thomas R. Fleming, Robert E. Schoen, Russell P. Tracy, Mary Cushman and G L Burke and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and American Journal of Epidemiology.

In The Last Decade

Cathy Tangen

35 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer: A Combined Analysis

2004 605 citations Cathy Tangen et al. The Journal of Urology profile →

Peers

Countries citing papers authored by Cathy Tangen

Since Specialization

Citations

This map shows the geographic impact of Cathy Tangen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cathy Tangen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cathy Tangen more than expected).

Fields of papers citing papers by Cathy Tangen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cathy Tangen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cathy Tangen. The network helps show where Cathy Tangen may publish in the future.

Co-authorship network of co-authors of Cathy Tangen

This figure shows the co-authorship network connecting the top 25 collaborators of Cathy Tangen. A scholar is included among the top collaborators of Cathy Tangen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cathy Tangen. Cathy Tangen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma 2019 ·European Urology Focus ·Hyung L. Kim, (unknown), Primo N. Lara, Edward M. Messing, Cathy Tangen, Brian Shuch, Ulka N. Vaishampayan	8
2	Background and Update for S1602 “A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-naïve High-grade Non-muscle-invasive Bladder Cancer 2018 ·European Urology Focus ·Robert S. Svatek, Cathy Tangen, Scott E. Delacroix, William T. Lowrance, Seth P. Lerner	38
3	PNFLBA-10 A PHASE III BLINDED STUDY OF IMMEDIATE POST-TURBT INSTILLATION OF GEMCITABINE VERSUS SALINE IN PATIENTS WITH NEWLY DIAGNOSED OR OCCASIONALLY RECURRING GRADE I/II NON-MUSCLE INVASIVE BLADDER CANCER: SWOG S0337 2017 ·The Journal of Urology ·Edward M. Messing, Cathy Tangen, Seth P. Lerner, Deepak M. Sahasrabudhe, Theresa M. Koppie, David P. Wood, Philip C. Mack, Robert S. Svatek, Christopher C. Evans, (unknown), Daniel J. Culkin, Timothy C. Brand, Lawrence I. Karsh, Jeffrey M. Holzbeierlein, Shandra Wilson, Guan Wu, Melissa Plets, Nicholas J. Vogelzang, Ian M. Thompson	2
4	Should Modest Elevations in Prostate-Specific Antigen, International Prostate Symptom Score, or Their Rates of Increase Over Time be Used as Surrogate Measures of Incident Benign Prostatic Hyperplasia? 2013 ·American Journal of Epidemiology ·(unknown), Rachel Hunter‐Merrill, Yingye Zheng, Ruth Etzioni, R. Gulati, Cathy Tangen, Ian M. Thompson, Alan R. Kristal	1
5	SWOG S0353: Phase II Trial of Intravesical Gemcitabine in Patients with Nonmuscle Invasive Bladder Cancer and Recurrence after 2 Prior Courses of Intravesical Bacillus Calmette-Guérin 2013 ·The Journal of Urology ·Eila C. Skinner, Bryan Goldman, Wael Sakr, Daniel P. Petrylak, Heinz‐Josef Lenz, Cheryl T. Lee, Shandra Wilson, Mitchell C. Benson, Seth P. Lerner, Cathy Tangen, Ian M. Thompson	105
6	Bladder, Penis and Urethral Cancer, and Basic Principles of Oncology Re: Do Mixed Histological Features Affect Survival Benefit from Neoadjuvant Platinum-Based Combination Chemotherapy in Patients with Locally Advanced Bladder Cancer? A Secondary Analysis of Southwest Oncology Group-Directed Intergroup Study (S8710) 2012 ·Emil Scosyrev, Benjamin Ely, (unknown), V. O. Speights, H. Barton Grossman, David P. Wood, Ralph W. de Vere White, N. Vogelzang, D L Trump, Ronald B. Natale, Cathy Tangen, Emily Crawford, Ian M. Thompson	14
7	Indications For and Use of Nonsteroidal Antiinflammatory Drugs and the Risk of Incident, Symptomatic Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention Trial 2012 ·American Journal of Epidemiology ·Jeannette M. Schenk, Gregory S. Calip, Cathy Tangen, Pamela J. Goodman, J. Kellogg Parsons, Ian M. Thompson, Alan R. Kristal	23
8	1666 SWOG S0353 PHASE II TRIAL OF INTRAVESICAL GEMCITABINE IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER WHO RECURRED FOLLOWING AT LEAST TWO PRIOR COURSES OF BCG 2012 ·The Journal of Urology ·Eila C. Skinner, Bryan Goldman, Wael Sakr, Daniel P. Petrylak, Heinz‐Josef Lenz, Cheryl T. Lee, Shandra Wilson, Seth P. Lerner, Cathy Tangen, Ian M. Thompson	5
9	Association of Symptomatic Benign Prostatic Hyperplasia and Prostate Cancer: Results from the Prostate Cancer Prevention Trial 2011 ·American Journal of Epidemiology ·Jeannette M. Schenk, Alan R. Kristal, Kathryn B. Arnold, Cathy Tangen, Marian L. Neuhouser, Daniel Lin, Emily White, Ian M. Thompson	46
10	Phase II Evaluation of Early Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel Combined With Hormonal Therapy in Patients With High-risk Metastatic Prostate Adenocarcinoma: Southwest Oncology Group S0032 2011 ·Urology ·David C. Smith, Cathy Tangen, Peter J. Van Veldhuizen, (unknown), Ali Golshayan, Glenn Mills, Nicholas J. Vogelzang, Ian M. Thompson, Maha Hussain	11
11	Circulating tumor cell capture and analysis in a multicenter SWOG-coordinated prostate cancer trial. 2010 ·Journal of Clinical Oncology ·Amir Goldkorn, Tao Xu, Binfeng Lu, A. S. Williams, (unknown), Cathy Tangen, P. Twardowski, Yu Chuan Tai, David I. Quinn, R. J. Cote	1
12	Paclitaxel gemcitabine (P-G) for patients (pts) with advanced urothelial cancer (UC) age > 70 years (yrs): SWOG 0028. 2010 ·Journal of Clinical Oncology ·Derek Raghavan, Cathy Tangen, Carol M. Moinpour, Carolyn Gotay, Kathy S. Albain, Stan G. Louie, H. J. Lenz, David I. Quinn, Mohammad Asif Hussain, Ian M. Thompson, (unknown)	3
13	Aneusomy for detection of bladder cancer recurrence: a Southwest Oncology Group study 2007 ·Cancer Genetics and Cytogenetics ·Sandra R. Wolman, Bryan Goldman, Marilyn L. Slovak, Cathy Tangen, Diane L. Persons, David P. Wood	4
14	Short- and long-term genitourinary symptom status and global quality of life (QOL) from a Southwest Oncology Group (SWOG) Trial 2005 ·Journal of Clinical Oncology ·Katherine Hayden, Carol M. Moinpour, James R. Faulkner, Cathy Tangen, Edith Canby‐Hagino, Dianne Lemmon, Sheila Breslin, Ian M. Thompson, Emily Crawford	1
15	Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression 2004 ·Urology ·Celestia S. Higano, Andrew Shields, (unknown), Judy Brown, Cathy Tangen	72
16	Increased Blood Glucose and Insulin, Body Size, and Incident Colorectal Cancer 1999 ·JNCI Journal of the National Cancer Institute ·Robert E. Schoen, Cathy Tangen, Lewis H. Kuller, G L Burke, Mary Cushman, Russell P. Tracy, Adrian S. Dobs, Peter J. Savage	400
17	Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. 1995 ·Journal of Clinical Oncology ·Cynthia G. Leichman, Thomas R. Fleming, Franco M. Muggia, Cathy Tangen, Bach Ardalan, James H. Doroshow, Frederick J. Meyers, Randall F. Holcombe, Geoffrey R. Weiss, A Mangalik	280
18	Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. 1995 ·Journal of Clinical Oncology ·C G Moertel, Thomas R. Fleming, J. S. Macdonald, Daniel G. Haller, John A. Laurie, Cathy Tangen, (unknown), (unknown), D C Tormey, John H. Glick	281
19	Phase II trial of amonafide in advanced pancreas cancer 1993 ·Investigational New Drugs ·Cynthia G. Leichman, Cathy Tangen, John S. Macdonald, (unknown), Thomas R. Fleming	7
20	Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study. 1992 ·Journal of Clinical Oncology ·Ronald M. Bukowski, Cathy Tangen, (unknown), J. S. Macdonald, A Einstein, Robert F. Peterson, Thomas R. Fleming	32

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact